| Literature DB >> 31146372 |
Adriano Costa de Camargo1, Bruno Trevenzoli Favero2, Maressa Caldeira Morzelle3, Marcelo Franchin4, Emilio Alvarez-Parrilla5, Laura A de la Rosa6, Marina Vilar Geraldi7, Mário Roberto Maróstica Júnior8, Fereidoon Shahidi9, Andrés R Schwember10.
Abstract
Legume seeds are rich sources of protein, fiber, and minerals. In addition, their phenolic compounds as secondary metabolites render health benefits beyond basic nutrition. Lowering apolipoprotein B secretion from HepG2 cells and decreasing the level of low-density lipoprotein (LDL)-cholesterol oxidation are mechanisms related to the prevention of cardiovascular diseases (CVD). Likewise, low-level chronic inflammation and related disorders of the immune system are clinical predictors of cardiovascular pathology. Furthermore, DNA-damage signaling and repair are crucial pathways to the etiology of human cancers. Along CVD and cancer, the prevalence of obesity and diabetes is constantly increasing. Screening the ability of polyphenols in inactivating digestive enzymes is a good option in pre-clinical studies. In addition, in vivo studies support the role of polyphenols in the prevention and/or management of diabetes and obesity. Soybean, a well-recognized source of phenolic isoflavones, exerts health benefits by decreasing oxidative stress and inflammation related to the above-mentioned chronic ailments. Similar to soybeans, chickpeas are good sources of nutrients and phenolic compounds, especially isoflavones. This review summarizes the potential of chickpea as a substitute for soybean in terms of health beneficial outcomes. Therefore, this contribution may guide the industry in manufacturing functional foods and/or ingredients by using an undervalued feedstock.Entities:
Keywords: cancer; cardiovascular disease; diabetes; genetics; inflammation; legume seeds; obesity; phenolic antioxidants
Mesh:
Substances:
Year: 2019 PMID: 31146372 PMCID: PMC6600242 DOI: 10.3390/ijms20112644
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Proximate composition (g/100 g) of chickpea and soybean.
| Component | Chickpea | Soybean | References |
|---|---|---|---|
| Ash | 2.54–3.90 | 4.42–6.29 | [ |
| Lipid | 1.12–6.80 | 14.9–23.3 | [ |
| Protein | 18.3–25.2 | 36.3–47.0 | [ |
| Soluble fiber | 1.23–1.38 | 9.05–9.33 | [ |
| Insoluble fiber | 14.1–23.2 | 18.2–21.2 | [ |
Total phenolic contents (mg GAE/g) of chickpea and soybeans.
| Feedstock | Organic Solvent * | References | ||
|---|---|---|---|---|
| Acetone | Ethanol | Methanol | ||
| Chickpea | 1.44–1.81 | 0.93–1.54 | 8.02–10.84 | [ |
| Soybean | 0.98–2.62 | 2.04–6.10 | 2.10–2.31 | [ |
* Only the organic solvent is mentioned. The concentration in water varies among different studies.
Isoflavone profile (%) of chickpea and soybean *.
| Compound | Chickpea | Soybean | Method | Reference |
|---|---|---|---|---|
| Formononetin | 2.61–16.6 | nd | UPLC-ESI-Q-TOF-MS, HPLC/MS | [ |
| Biochanin A | 17.8–30.0 | nd | UPLC-ESI-Q-TOF-MS, HPLC-ESI/MS | [ |
| Biochanin glucoside | 13.3–29.1 | nd | UPLC-ESI-Q-TOF-MS | [ |
| Daidzein | 0.30–20.0 | 0.32–7.65 | HPLC, UPLC-ESI-Q-TOF-MS, UPLC-ESI-Q-TOF-MS | [ |
| Daidzin | nd | 8.73–21.3 | UPLC-ESI-Q-TOF-MS | [ |
| Malonyldaidzin | nd | 20.5–28.1 | HPLC, UPLC-ESI-Q-TOF-MS, UPLC-ESI-Q-TOF-MS | [ |
| Genistein | 10.0–25.5 | 0.26–1.00 | HPLC, UPLC-ESI-Q-TOF-MS, UPLC-ESI-Q-TOF-MS, HPLC-ESI/MS | [ |
| Genistin | nd | 7.73–23.8 | HPLC, UPLC-ESI-Q-TOF-MS | [ |
| Malonylgenistin | nd | 36.0–42.5 | HPLC, UPLC-ESI-Q-TOF-MS | [ |
| Glycitein | nd | 0.78–0.97 | UPLC-ESI-Q-TOF-MS | [ |
| Glycitin | nd | 3.14–4.51 | HPLC, UPLC-ESI-Q-TOF-MS | [ |
| Malonylglycitin | nd | 1.93–7.98 | HPLC; UPLC-ESI-Q-TOF-MS | [ |
Abbreviations: HPLC, high-performance liquid chromatography; UPLC, ultra-performance liquid chromatography; ESI, electrospray ionization; Q, quadrupole; TOF, time of flight. * MS (mass spectrometry) may contemplate tandem mass spectrometry (MSn).
Scavenging of peroxyl radical and reducing power of chickpea and soybean.
| Method | Chickpea | Soybean | Reference |
|---|---|---|---|
| ORAC (µmol TE/g) | 8.74–52.2 | 22.2–86.8 | [ |
| FRAP (mmol Fe2+/g) | 0.73–1.13 | 1.24–1.96 | [ |
Abbreviations: ORAC, oxygen radical absorbance capacity; FRAP, Ferric reducing antioxidant power; TE, Trolox equivalents.
Figure 1Hydrolysis of triglyceride by lipase activity. R1, R2, and R3 are fatty acid residues.
Inhibition of α-glucosidase by soybean and chickpea phenolic extracts.
| Extraction | Identification | Methods | Main Findings | Reference |
|---|---|---|---|---|
| Chickpea 80% ethanol for free phenolics, NaOH hydrolysis for bound phenolics | Free (93 mg GAE/100 g sample) and bound (128 mg GAE/100 g sample) phenolic compounds | α-glucosidase inhibition index (GI = control activity/sample activity) | GI of 1.23 and 1.71 for free and bound phenolic extracts, respectively. Incubation of chickpea flour with | [ |
| Chickpea 80% methanol with 1% HCl | Phenolic acids: ferulic, | Enzyme inhibition (IC50) | IC50 = 92.2 µg/mL. Lower activity compared to underutilized Indian legumes (horse gram and cowpea). | [ |
| Chickpea 70% ethanol | Ferulic acid (9.1 mg/100 g), | Enzyme inhibition (%), enzyme source not specified | 15.9% inhibition. Lower inhibition compared to beans and peas, but higher than soybean. No correlation with phenolic acids nor antioxidant capacity. | [ |
| Chickpea 80% ethanol for free phenolics, NaOH hydrolysis for bound phenolics | Free (72 mg GAE/100 g sample) and bound (105 mg GAE/100 g sample) phenolic compounds | Enzyme inhibition (%), enzyme source not specified | 26 and 76% inhibition for free and bound phenolic extracts, respectively, obtained from brownies baked with chickpea flour. | [ |
| Chickpea 85% methanol | Total phenolic compounds, total flavonoids, total anthocyanins. | Rat intestinal α-glucosidase inhibition (%) | Between 16.2 and 43.6% inhibition. No correlation with and phenolic content nor antioxidant capacity. Germination increased inhibition. | [ |
| Soybean free (80% acetone) and bound (4 M NaOH) phenol extracts | Free (98 mg GAE/100 g sample) and bound (77 mg GAE/100 g sample) | Enzyme inhibition (IC50) | IC50 = 373 and 458 µg/mL for free and bound phenolic compounds, respectively. | [ |
| Solid state fermentation (SSF) and germinated soybean water extracts | 3–5 mg catechin equivalents (CE)/g for dry soybeans, 6–7 mg CE/g SSF, 4.5 mg CE/g sprouted soybean | α-glucosidase (yeast) inhibition index (GI = control activity/sample activity) | Approximately 1.1 GI for SSF and sprouted extracts. Less inhibition compared to α-amylase. | [ |
| Soybean 70% ethanol | Ferulic acid (14.69 mg/100 g), sinapic acid (5.41 mg/100 g), | Enzyme inhibition (%), enzyme source not specified | 12.06% inhibition. Lower inhibition compared to chickpea, beans, and peas. No correlation with phenolic acids nor antioxidant capacity. | [ |
| Acetone: water: acetic acid soybean extract. Fractionation of the extract with Amberlite XAD-7 resin | Total phenolic compounds, total flavonoids, total condensed tannins | Enzyme inhibition (IC50) | IC50 = 75.4 and 5.4 µg/mL for crude and tannin-rich extracts, respectively. Lower inhibition than black bean extracts. | [ |
| 70% methanol soybean phenolic extract | Total phenolic compounds (2.1 mg GAE/g). Glucosylated, molonylated, acetylated, and aglycone isoflavones: daidzein, genistein, and glycitein | Enzyme inhibition (%) of 1 mg/mL extract solution | Different methanol-water extracts were obtained. 70% of methanol showed the highest phenolic, isoflavone content, and enzyme inhibition (81%). | [ |
| 70% methanol hydroxylated and fermented soybean milk phenolic extract | Total phenols (3.7–6.6 mg GAE/g DW), total flavonoids (0.1–0.3 mg RE/g DW). Glucosylated and aglycone isoflavones: daidzein, genistein, and glycitein | Enzyme inhibition (%) of 0.5 mg/mL extract solution | 10 different varieties of soybean were analyzed. Enzyme inhibition between 32.4–55.5%. Glucosylated isoflavones decreased, and aglycones increased. | [ |
| Fermented soybean water extract | Total phenolic compounds (22.2–30.7 mg GAE/g) | Enzyme inhibition (IC50) | Different fungal strains. IC50 ranged between 27.4 and 41.0 mg/mL. | [ |
| Solid state fermentation (SSF) and germinated soybean water extracts | 3–5 mg catechin equivalents/g DW for dry soybeans, 6–7 mg CE/g DW SSF, 4.5 mg CE/g DW sprouted soybean | α-glucosidase (yeast) inhibition index (GI = control activity/sample activity) | Approximately 1.5–2.08 AI for SSF extracts and 1.3 AI for sprouted samples. | [ |
Abbreviations: GAE, gallic acid equivalent; CE, catechin equivalent; RE, rutin equivalent; DW, dry weight. IC50, the concentration necessary to inhibit enzymatic activity by 50%.
Inhibition of α-amylase by soybean and chickpea phenolic extracts.
| Extraction | Identification | Methods | Main Findings | Reference |
|---|---|---|---|---|
| Chickpea 80% ethanol for free phenolics, NaOH hydrolysis for bound phenolics | Free (93 mg GAE/100 g sample) and bound (128 mg GAE/100 g sample) phenolic compounds | α-amylase inhibition index (AI = control activity/sample activity) | AI of 1.9 and 1.66 for free and bound phenolic extracts, respectively. Incubation of chickpea flour with | [ |
| Chickpea 80% methanol with 1% HCl | Phenolic acids: ferulic, | Enzyme inhibition (IC50) | IC50 = 108.3 µg/mL. | [ |
| Chickpea water extract | Not identified (peptides and/or phenolic compounds) | Enzyme inhibition (%) | 34% inhibition. Lower inhibition compared to fava beans, peas, and lentils and similar to beans. Activity increased by processing. | [ |
| Chickpea water extract | Not identified (probably peptides) | Enzyme inhibition (%) | No inhibition. High activity in beans and soybean, reduced by soaking and cooking. | [ |
| Chickpea protein extracts | Not identified (probably peptides) | Enzyme inhibition (Units/g) | 16 different varieties evaluated for antinutritional factors. 0–15 Units/g, average 8.7. Activity lower than other pulses decreases by cooking. | [ |
| Soybean free (80% acetone) and bound (4 M NaOH) phenol extracts | Free (98 mg GAE/100 g sample) and bound (77 mg GAE/100 g sample) | Enzyme inhibition (IC50) | IC50 = 526 and 320 µg/mL for free and bound phenolic compounds, respectively. | [ |
| Acetone: water: acetic acid soybean extract. Fractionation of the extract with Amberlite XAD-7 resin | Total phenolic compounds, total flavonoids, total condensed tannins | Enzyme inhibition (IC50) | IC50 = 2.25 and 0.25 mg/mL for crude and tannin-rich extracts, respectively. Higher inhibition than black bean extracts. | [ |
| Water soybean phenolic extract | Not identified (probably peptides) | Enzyme inhibition (Units/g) | 939 and 899 units/g dry weight for raw and soaked soybeans, respectively. No inhibitory activity for cooked samples. | [ |
| Fermented soybean water extracts | Total phenolic compounds (2–12.7 mg CE/g DW), glucosidated and aglycone isoflavones: daidzein, genistein | Enzyme activity (units/g DW) | α-amylase activity increased during fermentation (39.3–128.2 units/g DW) depending on fermentation time and Bacillus species. | [ |
Abbreviations: GAE, gallic acid equivalent; CE, catechin equivalent; RE, rutin equivalent; DW, dry weight. IC50, the concentration necessary to inhibit enzymatic activity by 50%.
Inhibition of α-glucosidase by soybean and chickpea phenolic extracts.
| Extraction | Identification | Methods | Main Findings | Reference |
|---|---|---|---|---|
| Chickpea 80% methanol with 1% HCl | Not identified | Enzyme inhibition (IC50) | IC50 extract: 6.3 mg/mL. Higher activity than other pulses. No effect of in vitro digestion. | [ |
| Fermented soybean supplements 80% methanol extract | 75 ppm GAE non-fermented extract. 160 ppm GAE 60 h fermented extract. Aglycone flavonoids and isoflavones | Enzyme activity (% of control). 10 mg/mL extracts | Fermentation increased lipase inhibition and content of aglycone flavonoids and isoflavones. | [ |
| Soybean 80% methanol with 1% HCl | Not identified | Enzyme inhibition (IC50) | IC50 extract: 6.65–6.97 mg/mL. Similar activity to chickpea. | [ |
| Acetone: water: acetic acid soybean extract. Fractionation of the extract with Amberlite XAD-7 resin | Total phenolic compounds, total flavonoids, total condensed tannins | Enzyme inhibition (IC50) | IC50 = 0.27 and 0.081 mg/mL for crude and flavonoids rich extracts, respectively. | [ |
| 70% methanol hydroxylated and fermented soybean milk phenolic extract | Total phenols (3.7–6.6 mg GAE/g DW), total flavonoids (0.1–0.3 mg RE/g DW). Glucosylated and aglycone isoflavones: daidzein, genistein, and glycitein | Enzyme inhibition (%) of 0.5 mg/mL extract solution | 10 different varieties of soybean were analyzed. Enzyme inhibition between ND–43.4%. Glucosylated isoflavones decreased, and aglycones increased. | [ |
Abbreviations: GAE, gallic acid equivalent; RE, rutin equivalent; DW, dry weight. IC50, the concentration necessary to inhibit enzymatic activity by 50%.
Structure-activity relationship of flavonoids-digestive enzymes inhibition.
| Phenolics | Structure | α-amylase | α-glucosidase | Lipase | ||
|---|---|---|---|---|---|---|
|
| Ring A | Flav | Iso | Flav | Iso | Flav |
| -OH | ↑ | ↑ | ↑ | ↑ | ↑ | |
| -Gly | ↓ | ↓ | ↓ | |||
| -OMe | ↓ | ↓ | ↓ | |||
| Ring C | ||||||
| C2=C3 | ↑ | ↑ | ↑ | |||
|
| -OH | ↑ | ↑ | ↑ | ||
| C4=O | ↑ | ↑ | ↑ | |||
|
| -OMe | ↓ | ↓ | |||
| -OGalloyl | ↑ | ↑ | ↑ | |||
| -Gly | ↓ | ↓ | ↓ | ↕ | ||
| Ring B | ||||||
| O-Me | ↓ | ↑ | ↑ | |||
|
| -OH | ↑ | ↑ | ↕ | ||
| -Gly | ↓ | ↓ | ||||
Flav: Flavonoid. Iso: Isoflavone. -Gly: Glycosylation. -OGalloyl: attachment of a galloyl moiety to the hydroxyl group. ↑ increase in enzymatic inhibition. ↓ decrease in enzymatic inhibition. ↕ No systematic effect; it can increase or decrease the inhibitory activity depending on the flavonoid.
Figure 2Proposed mechanisms of action for the reduction of insulin resistance by soybeans and chickpeas. Abbreviations: ↓, decrease; ↑, increase; PPAR-γ, peroxisome proliferator-activated receptor-γ; HOMA-IR, homeostasis model assessment-insulin resistance; LDL-c: low-density lipoprotein cholesterol; HDL: high-density lipoprotein.
Chickpea, soybean, and isoflavones in the prevention of type 2 diabetes and obesity and associated metabolic biomarkers in vivo.
| Model | Treatment (Dose; Duration) | Main Findings | Reference |
|---|---|---|---|
|
| |||
| Animal | Male rats were fed a standard; HFD; or an HFD plus 10% raw crushed chickpea seeds diet for 8 months | Chickpeas: | [ |
| Clinical trial | Hypocaloric balanced diet + 4 servings/week of non-soybean legumes (lentils, chickpeas, peas, and faba beans) for 8 weeks in obese subjects | - Weight loss | [ |
| Clinical trial | Inclusion of 728 g chickpea per week for 12 weeks in healthy subjects in a crossover design | ↓ serum total cholesterol | [ |
| Clinical trial | Chickpea diet (140 g of canned, drained chickpeas, chickpea bread, and chickpea biscuits) for 5 weeks in hypercholesterolemic subjects in a randomized crossover design | ↓ serum LDL-c and total cholesterol concentrations | [ |
| Clinical trial | Randomized crossover design in healthy subjects: | ↓ glucose and insulin responses acutely | [ |
| Clinical trial | Inclusion of 728 g chickpea per week for 12 weeks in healthy subjects in a crossover design | ↓ fasting insulin concentration and HOMA-IR | [ |
|
| |||
| Clinical trial | 70 patients with type 2 diabetes were randomly divided: test group (35 people) with 60 g soy nut and control group (35 people) under the usual diet of diabetes for 8 weeks | ↓ fasting blood glucose | [ |
| Clinical trial | Randomized, double-blind, cross-over trial with 32 postmenopausal women with diet-controlled type 2 diabetes, supplemented with soy (30 g protein/day, 132 mg isoflavones/day) for 12 weeks | ↓ fasting insulin, insulin resistance, glycated hemoglobin | [ |
| Clinical trial | Randomized crossover clinical trial with 42 postmenopausal women with metabolic syndrome. Participants assigned to consume a control diet, a soy-protein diet, or a soy-nut diet each for 8 weeks. | ↓ insulin resistance, fasting plasma glucose | [ |
| Clinical trial | Diabetic patients (n = 77) were randomized prospective to the two treatments for 12 months: soy-based meal replacement, or individualized diet plan | Soy-based meal replacement presented greater values compared to the individualized diet plan: | [ |
| Animal | Soy isoflavone supplementation (0.1% | Soy isoflavone: ↓ body weight of obese rats | [ |
| Animal | HFD-induced insulin resistant rats treated with soy isoflavone with three different dosages (50 mg, 150 mg, and 450 mg/kg/day) for 30 days | ↓ fat pad weights | [ |
|
| |||
| Animal | Healthy normal mice divided into groups and intraperitoneally administered: dimethyl sulfoxide (DMSO) (control group) and genistein (50 mg/kg + 10% DMSO). Alloxan-induced diabetic male mice were treated with DMSO 10% and genistein (50 mg/kg + 10% DMSO) | Genistein: ↓ fasting glucose levels | [ |
| Animal | C57BL/6J mice were fed: low-fat diet; western-style diet, and western-style diet + 0.16% ( | Genistein and daidzein: ↓ food intake | [ |
Abbreviations: ↓, decrease; ↑, increase; HFD, high-fat diet; HOMA-IR, homeostasis model assessment-insulin resistance; MDA, malondialdehyde; PEPCK-C, Phosphoenolpyruvate carboxykinase; AMPK, activated protein kinase; ERK ½, extracellular signal-regulated kinase ½; LXR, Liver X Receptor.